PUBLICATIONS

Treatment of cancer-associated venous thromboembolism: a focus on special populations. Yannoutsos A, Cacciatore C, Jaouen S, Farge D, Frere C. J Med Vasc. 2023. In press.

External validation of the IMPEDE VTE score for predicting venous thromboembolism in patients with newly diagnosed multiple myeloma receiving immunomodulatory drugs: a retrospective cohort study. Frere C et al. STH Academy. 2023; 392096; OC 36.4.

Direct oral anticoagulants versus low molecular weight heparins in patients with brain tumor receiving therapeutic anticoagulation: a systematic review and meta-analysis.  Frere C et al. ISTH Academy 2023; 382012; PB0938.

Venous thromboembolism and breast cancer. Crichi B, Moati E, Cacciatore C, Farge D, Frere C. Bull Cancer. 2023 Jul 18:S0007-4551(23)00296-5.

The 2022 ITAC evidence-based clinical practice guidelines: New update from the International Initiative on Thrombosis and Cancer to improve the care in patients with cancer-associated thrombosis. Frere C, Farge D, Douketis J, Connors JM. J Med Vasc. 2022; 47: 113-115. [DOI: 10.1016/j.jdmv.2022.08.002].

Comparison of the Khorana, PROTECHT and ONKOTEV risk assessment models to predict venous thromboembolism in patients with pancreatic cancer [abstract]. Frere C, Gauthier L, Canivet C, Gourgou S, Buscail L, Bournet B, Farge D. https://abstracts.isth.org/abstract/comparison-of-the-khorana-protecht-and-onkotev-risk-assessment-models-to-predict-venous-thromboembolism-in-patients-with-pancreatic-cancer/. Accessed August 28, 2022.

The Ottawa Score did not predict recurrent venous thromboembolism in the prospective TROPIQUE cohort study [abstract]. Frere C, Debourdeau P, lamblin A, Cajfinger F, Falvo N, Benhamou Y, Sevestre M, Farge D. https://abstracts.isth.org/abstract/the-ottawa-score-did-not-predict-recurrent-venous-thromboembolism-in-the-prospective-tropique-cohort-study/. Accessed August 28, 2022.

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Munoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J, and the International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Lancet Oncology. July, 2022. DOI:https://doi.org/10.1016/S1470-2045(22)00160-7.

A review of latest clinical practice guidelines for the management of cancer-associated thrombosis. Frere C, Wahl C, Rueda-Camino JA, Crichi B, Prata PH, Marjanovic Z, Farge D. Best Pract Res Clin Haematol. 2022 May 28. Online ahead of print. doi.org/10.1016/j.beha.2022.101348

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. Trujillo-Santos J, Farge-Bancel D, Pedrajas JM, Gómez-Cuervo C, Ballaz A, Braester A, Mahé I, Villalobos A, Porras JA, Monreal M; RIETE Investigators. Res Pract Thromb Haemost. 2022 Jun 3;6(4):e12736. doi: 10.1002/rth2.12736.

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. Frere C, Farge D, Schrag D, Prata PH, Connors JM. J Hematol Oncol. 2022 May 21;15(1):69. doi: 10.1186/s13045-022-01289-1.

Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. Frere C, Crichi B, Rueda-Camino J, Cajfinger F, Spiess N, Janus N, Le Maignan C, Marjanovic Z, Farge D. J Med Vasc. 2022 May 20. Online ahead of print. [DOI: 10.1016/j.jdmv.2022.04.004]

Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors. Lecumberri R, Ruiz-Artacho P, Tzoran I, Brenner B, Farge Bancel D, Ay C, Rosa V, Iria F, Hernández-Blasco L, Trujillo Santos J, Monreal M. Thromb Haemost. 2022 Feb 21. doi: 10.1055/a-1777-4006. Epub ahead of print.

Direct Oral Anticoagulant Versus Low Molecular Weight Heparin for the Treatment of Cancer-Associated Thromboembolism: 2021 Updated Meta-Analysis of Randomized Controlled Trials. Frere C, Farge D, Schrag D, Prata PH P, Connors JM. Blood 2021; 138 (Supplement 1): 668. doi: https://doi.org/10.1182/blood-2021-150696

Patient education program at the forefront of cancer-associated thrombosis care. Sebuhyan M, Crichi B, Deville L, Le Maignan C, Bonnet C Marjanovic Z, Rueda J, Bensaoula O, Ndour A, Frere C, Madeleine I, Farge D. J Med Vasc. 2021 Aug 25. Online ahead of print. [DOI: 10.1016/j.jdmv.2021.08.001]

Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study. Benzidia I, Crichi B, Montlahuc C, Rafii H, N’Dour A, Sebuhyan M, Gauthier H, Ait Abdallah N, Benillouche P, Villiers S, Le Maignan C, Farge D. J Thromb Thrombolysis. 2021 Jul 22. Online ahead of print. [DOI: 10.1007/s11239-021-02512-5]

Development of a Multi-language Mobile App to Implement the 2019 ITAC Clinical Practice Guidelines for the Treatment and Prophylaxis of Venous Thromboembolism in Cancer Patients. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss (in memoriam) S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J. Res Pract Thromb Haemost. 2021; 5 (Suppl 1).

Update on Guidelines for the Management of Cancer-Associated Thrombosis.
Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G.
Oncologist. 2021 Jan;26(1):e24-e40. doi: 10.1002/onco.13596. Epub 2020 Dec 4.

The Burden of Venous Thromboembolism in Pancreatic Cancer. Frere C, on behalf of the Groupe Francophone Thrombose et Cancer. World J Gastroenterol 2021; 27(19): 2325-2340 [DOI: 10.3748/wjg.v27.i19.2325]

Incidence, predictors and clinical outcomes of venous thromboembolism in patients with newly diagnosed pancreatic ductal adenocarcinoma: results of the prospective BACAP-VTE study. Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D on behalf of the Groupe Francophone Thrombose et Cancer and the BACAP Consortium. Thromb Res. 2021 Mar; 200 Suppl 1:S4. doi.org/10.1016/S0049-3848(21)00146-8

What is the current state of thrombosis treatment and prevention in cancer patients?
Farge D. J Med Vasc. 2020 Nov;45(6S):6S1-6S2. doi: 10.1016/S2542-4513(20)30512-5.

Management of Cancer-Associated Thrombosis: An Evolving Area.
Frere C, Connors JM, Farge D. Cancers (Basel). Cancers 2020, October; 12(10), 2999; oi.org/10.3390/cancers12082028

Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Frere C, Crichi B, Bournet B, Canivet C, AIt Abdallah N, Buscail L, Farge D. Cancers (Basel). Cancers 2020, July; 12(8), 2028; doi.org/10.3390/cancers12082028

Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.
Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D; BACAP Consortium. Gastroenterology. 2020 Apr;158(5):1346-1358.e4. doi: 10.1053/j.gastro.2019.12.009.

Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented.
Farge D, Bournet B, Conroy T, Vicaut E, Rak J, Zogoulous G, Barkun J, Ouaissi M, Buscail L, Frere C. Cancers (Basel). 2020 Mar 6;12(3). pii: E618. doi: 10.3390/cancers12030618.

Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines.
Rafii H, Frere C, Benzidia I, Crichi B, Andre T, Assenta E, Bournet B, Carpentier A, Connault J, Doucet L, Durant C, Emmerich J, Gris JC, Hij A, Le Hello C, Madeleine I, Messas E, N(Dour A, Villiers S, Marjanovic Z, Ait Abdallah N, Yannoutsos A, Farge D. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). J Med Vasc. 2020 Feb;45(1):28-40. doi: 10.1016/j.jdmv.2019.12.004

New progress in the treatment and prophylaxis of venous thrombo-embolism in cancer patients.
Connors JM, Farge D. J Med Vasc. 2020 Feb;45(1):2. doi: 10.1016/j.jdmv.2019.12.005

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. 
Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 Lancet Oncol. 2019 Sep 3. pii: S1470-2045(19)30336-5. doi: 10.1016/S1470-2045(19)30336-5.

Women, thrombosis, and cancer. 
Farge D, Le Maignan C, Doucet L, Frere C. Thromb Res. 2019 Sep;181 Suppl 1:S47-S53. doi: 10.1016/S0049-3848(19)30367-6.

Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. 
Farge D, Frere C. F1000 Research 2019, 8(F1000 Faculty Rev):974

Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE database.
Fuentes HE, Tafur AJ, Caprini JA, Alatri A, Trujillo-Santos J, Farge-Bancel D, Rosa V, Font L, Vilaseca A, Monreal M; RIETE Investigators. Int Angiol. 2019 May 16. doi: 10.23736/S0392-9590.19.04110-5

Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. 
Frere C, Benzidia I, Marjanovic Z, Farge D.Cancers (Basel). 2019 Jan 10;11(1). pii: E71. doi: 10.3390/cancers11010071.

The best direct-acting oral anticoagulant for treatment of venous thromboembolism?
Frere C, Farge D. Lancet Haematol. 2018 Dec 14. pii: S2352-3026(18)30211-4. doi: 10.1016/S2352-3026(18)30211-4.

Treatment of cancer associated thrombosis: Which role for direct oral anticoagulants in 2018?
Frere C, Farge D. J Med Vasc. 2018 Sep;43(5):293-301.

Edoxaban for Cancer-Associated Venous Thromboembolism.
Frere C, Dufilho M. N Engl J Med. 2018 Jul 5;379(1):94. doi: 10.1056/NEJMc1806646.

Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC).
Farge D, Cajfinger F, Falvo N, Berremili T, Couturaud F, Bensaoula O, Védrine L, Bensalha H, Bonnet I, Péré-Vergé D, Coudurier M, Li V, Rafii H, Benzidia I, Connors JM,* and Resche-Rigon M. Oncotarget. 2018; 9:26990-26999.

Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry.
Frere C, Trujillo-Santos J, Font C, Sampériz Á, Quintavalla R, González-Martínez J, Vázquez FJ, Lima J, Farge D, Monreal M; RIETE Investigators. Thromb Haemost. 2018 Apr 21. doi: 10.1055/s-0038-1642009.

Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.
Kuperman A, Lopez-Reyes R, Bosco LJ, Lorenzo A, Jose B, Farge-Bancel D, Alfonso M, Lumbierres M, Stemer G, Monreal Bosch M, Braester A; RIETE Investigators. J Thromb Thrombolysis. 2018 Jan 30. doi: 10.1007/s11239-018-1610-9.

Implementation of international good clinical practice guidelines to improve care of patients with cancer-related venous thromboembolism. 
Qari R, Frere C, Farge D, El Ayoubi H. Journal of Applied Hematology. 2017. 8; 42 (3) : 85-98.doi: 10.4103/joah.joah_32_17

Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function.
Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MP, Büller HR, Elias A, Farge D, Konstantinides S, Palareti G, Prandoni P, Righini M, Torbicki A, Vlachopoulos C, Brodmann M.Eur Heart J. 2017 Feb 17. doi: 10.1093/eurheartj/ehx003.

Women, thrombosis, and cancer: A gender-specific analysis.
Farge D, Bounameaux H, Bauersachs RM, Brenner B. Thromb Res. 2017 Mar;151 Suppl 1:S21-S29. doi: 10.1016/S0049-3848(17)30062-2.

Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism.
Trujillo-Santos J, Martos FM, Font C, Farge-Bancel D, Rosa V, Lorenzo A, Barrón M, Lorente MA, Pedrajas JM, Monreal M. Heliyon. 2017 Jan 16;3(1):e00229. doi: 10.1016/j.heliyon.2016.e00229.

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
Farge D, Bounameaux H, Brenner H, Cajfinger F, Debourdeau P, Khorana A, Pabinger I, Solymoss S, Douketis J, Kakkar A
Lancet 0ncology October 2016 ; 27 :10

Clinical practice guidelines for prophylaxis of venous thomboembolism in cancer patients.
Frere C, Farge D.
Thromb Haemost. 2016 Sep 27;116(4):618-25. doi: 10.1160/TH16-04-0302. Epub 2016 Aug 25.

The origin and concentration of circulating microparticles differ according to cancer type and evolution: A prospective single-center study.
Mege D, Panicot-Dubois L, Ouaissi M, Robert S, Sielezneff I, Sastre B, Dignat-George F, Dubois C.
Int J Cancer. 2016 Feb 15;138(4):939-48. doi: 10.1002/ijc.29837. Epub 2015 Oct 1.

Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism.
Farge D, Trujillo-Santos J, Debourdeau P, Bura-Riviere A, Rodriguez-Beltrán EM, Nieto JA, Peris ML, Zeltser D, Mazzolai L, Hij A, Monreal M; RIETE Investigators.
Medicine (Baltimore). 2015 Aug;94.

Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo.
Mezouar S1, Darbousset R, Dignat-George F, Panicot-Dubois L, Dubois C. Int. J. Cancer. 2015; Jan 15;136(2):462-75.

Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice.
ThomasGM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, Wagner DD. J Thromb Haemost. 2015 Jul;13:1310-9.

Involvement of platelet-derived microparticles in tumor progression and thrombosis.
Mezouar S, Mege D, Darbousset R, Farge D, Debourdeau P, Dignat-George F, Panicot-Dubois L, Dubois C.
Semin Oncol. 2014 Jun;41(3):346-58. doi: 10.1053/j.seminoncol.2014.04.010.

Implementing thrombosis guidelines in cancer patients: a review.
Farge-Bancel D, Bounameaux H, Brenner B, Büller HR, Kakkar A, Pabinger I, Streiff M, Debourdeau P.
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0041. doi: 10.5041/RMMJ.10175.

Therapy for cancer-related thromboembolism.
Frere C, Debourdeau P, Hij A, Cajfinger F, N’Guessan M, Panicot-Dubois L, Dubois C, Farge D.
Semin Oncol. 2014 Jun;41(3):319-38. doi: 0.1053/j.seminoncol.2014.04.005.

The Subcommittee on Haemostasis Malignancy.Prevention of VTE in Cancer Outpatients: guidance from the SSC of the ISTH
Khorana AA, Otten HM, Zwicker JI, Connolly GC, Farge-Bancel D, Pabinger I; J Thromb Haemost. 2014;12:1928-31

International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer.
Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Büller HR, Bounameaux H. .
J Thromb Haemost. 2013 Jan;11(1):71-80. doi: 10.1111/jth.12071.PMID: 23217208

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR..
J Thromb Haemost. 2013 Jan;11(1):56-70. doi: 10.1111/jth.12070